⌘K
Loading ticker…
Invesco Biotechnology & Genome ETF · Other
3m RS is unavailable, Market Stance is 47.8
As of 2026-08-24, Invesco Biotechnology & Genome ETF (PBE) has a 3-month relative strength percentile of — within the TickerStance CS+ADRC universe (~5,000 tickers). The current market Stance is 47.8 (Neutral). Sector: Other. Average daily range 1.2%, relative volume 0.92×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
| # | Holding | Weight | Value |
|---|---|---|---|
| 1 | UTHR | 6.28% | $16M |
| 2 | ILMN | 5.37% | $13M |
| 3 | BIIB | 5.05% | $12M |
| 4 | INCY | 4.91% | $12M |
| 5 | ALNY | 4.84% | $12M |
| 6 | REGN | 4.77% | $12M |
| 7 | AMGN | 4.71% | $12M |
| 8 | GILD | 4.62% | $11M |
| 9 | BCRX | 3.42% | $8M |
| 10 | CPRX | 3.30% | $8M |
| 11 | ARWR | 3.28% | $8M |
| 12 | Protagonist Therapeutics, Inc. | 3.22% | $8M |
| 13 | TGTX | 3.15% | $8M |
| 14 | RPRX | 3.13% | $8M |
| 15 | CDNA | 3.07% | $8M |
| 16 | NBIX | 2.86% | $7M |
| 17 | EXEL | 2.80% | $7M |
| 18 | TECH | 2.73% | $7M |
| 19 | PTCT | 2.68% | $7M |
| 20 | VCYT | 2.62% | $6M |
| 21 | ACAD | 2.59% | $6M |
| 22 | VCEL | 2.58% | $6M |
| 23 | HALO | 2.57% | $6M |
| 24 | RGEN | 2.50% | $6M |
| 25 | TBPH | 2.49% | $6M |
Showing 25 of 30 holdings.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
No attention data for this ticker yet — it joins the daily scan once a baseline builds.
Daily range, ATR, beta, and the math for a 1-ADR stop.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PBE Jan avg: 1.69% median: 1.96% win: 50% σ: 3.60% n: 4 2022-04-12 → 2026-07-31 | PBE Feb avg: -1.62% median: -1.85% win: 50% σ: 3.18% n: 4 2022-04-12 → 2026-07-31 | PBE Mar avg: -2.74% median: -2.37% win: 0% σ: 1.75% n: 4 2022-04-12 → 2026-07-31 | PBE Apr avg: -3.32% median: -1.83% win: 20% σ: 4.06% n: 5 2022-04-12 → 2026-07-31 | PBE May avg: 1.48% median: 1.26% win: 80% σ: 3.48% n: 5 2022-04-12 → 2026-07-31 | PBE Jun avg: 2.96% median: 2.38% win: 100% σ: 2.29% n: 5 2022-04-12 → 2026-07-31 | PBE Jul avg: 3.86% median: 3.53% win: 80% σ: 3.24% n: 5 2022-04-12 → 2026-07-31 | PBE Aug avg: 0.85% median: 0.77% win: 50% σ: 3.46% n: 4 2022-04-12 → 2026-07-31 (current) | PBE Sep avg: -2.67% median: -2.70% win: 25% σ: 3.85% n: 4 2022-04-12 → 2026-07-31 | PBE Oct avg: 1.59% median: 2.39% win: 50% σ: 6.84% n: 4 2022-04-12 → 2026-07-31 | PBE Nov avg: 7.27% median: 7.19% win: 100% σ: 3.71% n: 4 2022-04-12 → 2026-07-31 | PBE Dec avg: 0.16% median: -3.05% win: 25% σ: 8.33% n: 4 2022-04-12 → 2026-07-31 |
Holdings of PBE currently on TickerStance stock-RS leaderboards.
Metrics matched 28 tickers across 30 holdings rows (93.5% of fund weight). Metrics as of 2026-08-24; holdings from the filing.